+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rotavirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 131 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5970020
The 7 major rotavirus markets are expected to exhibit a CAGR of 8.62% during 2023-2034.

The rotavirus market has been comprehensively analyzed in this report titled "Rotavirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rotavirus infection is a viral illness that predominantly impacts infants and young children, resulting in gastroenteritis characterized by inflammation in the stomach and intestines. Some of the common symptoms associated with the ailment include severe watery diarrhea, often accompanied by vomiting, fever, abdominal pain, and dehydration. The diarrhea can be frequent and persistent, leading to fluid loss and electrolyte imbalances. In infants and young children, the indications can be particularly severe, potentially causing life-threatening dehydration. Various other signs may include loss of appetite, irritability, general discomfort, etc. The diagnosis of the condition typically involves a combination of clinical evaluation, laboratory testing, and symptom assessment. Healthcare providers may inquire about the patient's medical history and conduct a physical examination to assess symptoms like diarrhea, vomiting, fever, etc. Numerous laboratory procedures, such as enzyme immunoassay (EIA) or rapid antigen detection tests, are commonly used to detect the presence of rotavirus in stool samples. These tests identify the viral antigens and genetic material of the rotavirus. In some cases, a polymerase chain reaction (PCR) test may be performed for confirmation.

The increasing cases of direct contact with an infected person through activities like hugging, kissing, sharing utensils, etc., which can facilitate the transmission of the virus, are primarily driving the rotavirus market. Furthermore, the rising prevalence of numerous associated risk factors, including poor hygiene practices, weakened immune systems, crowded environments, etc., is creating a positive outlook for the market. Apart from this, the escalating utilization of antiemetic medications, such as ondansetron, for reducing nausea and vomiting, thereby improving the patient's ability to tolerate oral rehydration, is also bolstering the market growth. Moreover, several key players are making extensive investments in R&D activities to introduce effective monoclonal antibodies that target specific components of the virus, inhibiting its ability to infect host cells and replicate. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of fecal microbiota transplantation (FMT), which involves manipulating the gut microbiota to improve gut function and reduce the severity of symptoms, is expected to drive the rotavirus market during the forecast period.

This report provides an exhaustive analysis of the rotavirus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for rotavirus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rotavirus market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the rotavirus market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the rotavirus market

Competitive Landscape:

This report also provides a detailed analysis of the current rotavirus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the rotavirus market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the rotavirus market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the rotavirus market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of rotavirus across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of rotavirus by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of rotavirus by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with rotavirus across the seven major markets?
  • What is the size of the rotavirus patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of rotavirus?
  • What will be the growth rate of patients across the seven major markets?

Rotavirus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for rotavirus drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rotavirus market?
  • What are the key regulatory events related to the rotavirus market?
  • What is the structure of clinical trial landscape by status related to the rotavirus market?
  • What is the structure of clinical trial landscape by phase related to the rotavirus market?
  • What is the structure of clinical trial landscape by route of administration related to the rotavirus market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Rotavirus - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Rotavirus - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Rotavirus - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Rotavirus - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Rotavirus - Unmet Needs10 Rotavirus - Key Endpoints of Treatment
11 Rotavirus - Marketed Products
11.1 List of Rotavirus Marketed Drugs Across the Top 7 Markets
11.1.1 Rotarix (Rotavirus vaccine) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 RotaTeq (Rotavirus W179-9 vaccine) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 Rotavirus - Pipeline Drugs
12.1 List of Rotavirus Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. Rotavirus - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Rotavirus - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Rotavirus - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Rotavirus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Rotavirus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Rotavirus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Rotavirus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Rotavirus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Rotavirus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Rotavirus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Rotavirus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Rotavirus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Rotavirus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Rotavirus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Rotavirus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Rotavirus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Rotavirus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Rotavirus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Rotavirus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Rotavirus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Rotavirus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Rotavirus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Rotavirus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Rotavirus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Rotavirus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Rotavirus - Access and Reimbursement Overview
16 Rotavirus - Recent Events and Inputs From Key Opinion Leaders
17 Rotavirus Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Rotavirus Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...